Publications by authors named "R A Gottlieb"
Background And Aims: Recurrent myocardial infarction (MI) and incident heart failure (HF) are major post-MI complications. Herein, contemporary post-MI risks for recurrent MI and HF are described.
Methods: A total of 6804 patients with a primary discharge diagnosis of MI at 28 Baylor Scott & White Health hospitals (January 2015 to December 2021) were studied.
Safety and Effectiveness of Yttrium-90 Radioembolization in People Living with HIV.
J Vasc Interv Radiol
January 2025
Purpose: To investigate if Yttrium-90 radioembolization (Y90 TARE) is a safe and effective treatment in people living with HIV (PLWH) with hepatocellular carcinoma (HCC) across the BCLC stage spectrum.
Materials And Methods: A retrospective review was conducted of all patients with HCC presented at a multidisciplinary institutional liver tumor board who underwent Y90 TARE between January 2014 and June 2023. Thirty-nine patients with documented HIV seropositivity prior to Y90 TARE and adherence to HAART were included.
Article Synopsis
- * Researchers administered a drug called PR-364 to mice after a heart attack, finding it significantly reduced mortality, preserved heart function, and slowed heart failure progression.
- * The findings revealed that PR-364 boosted the removal of damaged mitochondria and improved energy production in heart cells, suggesting it could be a promising treatment to protect heart tissue after a heart attack.
Article Synopsis
- * A 12-week exercise program was studied, showing that those who participated had a significant decrease in pulmonary capillary wedge pressure, indicating better heart performance during mild exercise compared to those who maintained their usual activity.
- * Additional benefits were observed in the exercise group, including improved peak oxygen consumption, cardiac index, and overall quality of life, suggesting that physical training is effective for enhancing cardiac function and exercise capacity among these patients.
Background: Reducing hospital readmission offer potential benefits for patients, providers, payers, and policymakers to improve quality of healthcare, reduce cost, and improve patient experience. We investigated effectiveness of remdesivir in reducing 30-day coronavirus disease 2019 (COVID-19)-related readmission during the Omicron era, including older adults and those with underlying immunocompromising conditions.
Methods: This retrospective study utilized the US PINC AI Healthcare Database to identify adult patients discharged alive from an index COVID-19 hospitalization between December 2021 and February 2024.